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ABSTRACT

An Electrochemical Immunoassay System for Measuring Circulating Protein Biomarkers of
Pediatric Soft Tissue Sarcoma
by
Ivy Antwi

Measurement of circulating protein biomarkers associated with disease can facilitate early
detection, help guide treatment strategies and improve patient outcomes beyond current standards
of care. The combination of inexpensive 3D-printed flow cells and electrochemical biosensors has
recently emerged as a viable platform for low-cost, reliable biomarker measurements. Here, we
report an electrochemical immunoassay system based on simple graphite electrode arrays, 3Dprinted flow cells, and signal-generating magnetic bead bioconjugates for simultaneous detection
of three biomarker proteins (cancer antigen 125 (CA 125), midkine (MK) and osteopontin (OPN))
associated with pediatric soft tissue sarcomas. Magnetic bead bioconjugates are functionalized
with large amounts of antibody and enzyme labels, electrode arrays are modified with gold
nanoparticles and antibodies for specific capture of bioconjugate-labeled biomarkers, and 3Dprinted flow cells facilitate their amperometric detection. Using this system, detection limits for
CA 125, OPN and MK are 100 times lower than those obtained with commercial enzyme-linked
immunosorbent assay.
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CHAPTER 1. INTRODUCTION
Biomarkers and Disease
Biomarkers have been defined broadly by the World Health Organization as ‘any
measurable process, substance, structure or products of reactions in the body that can predict or
influence the incidence of outcome or disease’.1,2 Measurements of biomarker levels can be used
to determine a person’s health status or predict the outcome of a disease.3 For example, heart rate
on an electrocardiogram serves as a biomarker to check damage to the heart, and blood glucose
level is a biomarker for diabetic ketoacidosis.4 The quality of biomarkers can be characterized in
terms of parameters known as sensitivity and selectivity. Ideal biomarkers exhibit high
specificity (low false positive rate) and sensitivity (low false negative rate).5
Since some circulating proteins are over- or under-expressed in the body due to certain
diseases or health conditions, proteins are an important class of biomarkers. One example of a
protein biomarker is C-reactive protein, which gives information about the rate of inflammation
in colons of cancer patients.6 For effective indication of the current medical state of a person,
protein biomarkers must be measured accurately and reproducibly in serum, blood, urine, or soft
tissue samples. The most widely used technique in clinical analysis of protein biomarkers
continues to be traditional enzyme-linked immunosorbent assay (ELISA).7
Enzyme-linked Immunosorbent Assay
ELISA is based on the specific binding interaction between an antibody and the
biomarker of interest (antigen), and an optical signal (e.g., optical density or absorbance)
generated by an enzyme reaction (Figure 1). There are a few different forms on ELISA such as
direct, indirect, competitive and sandwich ELISA.8 However, the most common is the sandwichtype due to its high sensitivity.8
12

Figure 1. An illustrated schematic diagram for sandwich-type immunoassay
In sandwich-type ELISA, a primary antibody that has high specificity for the antigen is
bound onto a surface such as the wells in a microtiter plate. The sample (e.g., serum) is delivered
into the well so that the antigen can be captured by the primary antibody and thus isolated from
the rest of the sample matrix. Following washing steps to remove unbound or weakly bound
materials, a second antibody, labeled with an enzyme, is introduced into the wells where it binds
to the captured analyte, forming a sandwich-like bioconjugate. Detection of analyte is achieved
by adding an enzyme substrate which strongly absorbs visible light upon reaction with the
enzyme.7 The most commonly used enzymes in ELISA are horseradish peroxidase (HRP) and
alkaline phosphatase (ALP) which are activated by hydrogen peroxide and p-nitrophenylphosphate, respectively. In the case of HRP, the addition of hydrogen peroxide oxidizes Fe(III)
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center which generates an optical signal in the form of a color change upon the addition of a
substrate like 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS).8-11
ELISAs are very useful techniques in quantifying protein biomarkers in serum and other
biological fluids. Typical ELISA techniques exhibit detection limits ranging from 1-100 pg/ml
(picogram per milliliters) which are insufficient for detection of protein biomarkers of cancer at
early stages.12 They also pose great challenges due to other limitations, such as long analysis
time and relatively large sample volume requirements (typically 100 µl). ELISA techniques are
also typically confined to centralized lab settings with requisite instrumentation and expertise,
and they are poorly suited for measurements of more than a single protein biomarker in a given
aliquot of sample.13
While interest in identifying and studying biomarkers has been well-established for
decades, contemporary advances in research and technology have enabled more convenient and
effective capture, isolation, detection, and characterization of biomarker proteins in clinical
samples.14 These advances and continuing accumulation of knowledge of the relationship
between diseases and circulating proteins, has also led to a strong emphasis on the development
of biomarker panels (i.e., collections of proteins). The interest in biomarker panels stems from
the highly complex and diverse nature of diseases such as cancers, which often renders single
protein measurements insufficient in terms selectivity and specificity for a particular disease.15
A few commercialized techniques are suitable for measuring protein biomarker panels.
Modern liquid chromatography-mass spectrometry (LC-MS) proteomics has been able achieve
multiple protein biomarker measurements in clinical samples. LC-MS proteomics also typically
has acceptable sensitivity and a lower limit of detection as compared to traditional ELISA.
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However, it is very expensive and also involves quite complex instrumentation and techniques
and, as such, very difficult to be used outside of clinical settings.7,12
Another technique with high sensitivity and selectivity that can be employed in
biomarker detection is the single molecule array (Simoa™), which has recently been
commercialized by David Walt.16 This system is similar to conventional ELISA. However, in
place of a single antibody labeled with a single enzyme, an enzyme-labeled immunocomplex is
formed on a paramagnetic bead (MB) that features many copies of a specific antibody. The MB
immunocomplex is subsequently isolated in a single well of femtoliter volume prepared from an
array of etched optical fibers. The diameter of each well is such that only a single MB
immunocomplex can fit.17 This system requires proprietary reagents, sophisticated
instrumentation, and a centralized lab for sample processing.
Thus, inexpensive, simple, easy to operate and reliable sensing systems and strategies for
measuring multiple protein biomarkers remains a largely unmet challenge that is the subject of
continuing research and development. Strategies for analyzing clinical samples for multiple
protein biomarkers based on electrochemical measurements (e.g., electrochemical
immunoassays) have gained great attention due to low cost, lack of maintenance and relative
ease of miniaturization associated with electrochemical instruments, and relative ease at which
sensitive analytes can be measured electrochemically in low sample volumes.18,19
Electrochemical Immunoassay and Immunosensors
Electrochemical immunoassays were first reported by Heineman et al. in 1979.20,21 In
electrochemical immunoassays, an amperometric, conductometric, or potentiometric signal is
generated as the bioreceptor (antibody) interacts with the antigen, and the electrochemical signal
is used to determine the antigen (target analyte) concentration.10,11,19,22 While there are several
15

different forms of electrochemical immunoassays, many are based on the sandwich-type strategy
(Figure 2) where an antibody (biorecognition molecule) is immobilized on an electrode surface
to specifically bind an antigen (target analyte) and the electrochemical signal is generated by a
label (e.g., enzyme, metal nanoparticle, redox species) that is attached to another antibody which
also binds to the antigen.23 Strategies where an enzyme label is used to generate the
electrochemical signal are forms of ELISA with electrochemical detection (i.e., electrochemical
ELISA).24

Figure 2. Illustration of an electrochemical sandwich-type ELISA
Many electrochemical immunoassay strategies have since been developed and reported to
increase sensitivity (Table 1). One way of enhancing signal is by increasing the number of
signal-generating labels on the detection antibodies, which can be done by providing support
such as polymers or magnetic microbeads.3
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Table 1. List Of Some Antigen, Labels and Electrodes Used in Electrochemical Immunoassays
with its Limit of Detection
Target
Antigen
(IL)-8
mRNA &
(IL)-8

Label

Electrode

LOD

Linear Range

Ref

Antifluorescein- StreptavidinHRP
coated Au
HRP-Ab2
electrode

3.9 fM

5fM - 50pM

25

7.4 pg/ml

10 - 500 pg/ml

PSA

Ab2-MB-HRP

AuNP Pyrolytic
graphite
electrode

0.5 pg/ml

0 -10 pg/ml

81

IL-6

MWCNT-HRPAb2

SWNT forest
electrode

0.5 pg/ml

0.5 - 5pg/ml

26

f-PSA

Ab2-HRP

MB - SPCE

< 0.1 ng/ml

0 - 1 ng/ml

27

PSA

Ab2 -AP

SPCE

1.4 ng/ml

0 – 20 ng/ml

28

CEA

MB-Au-HRP

AuNP-CFME

10 pg/ml

0.01 -160 ng/ml

29

AFP

No label

MWCNT-Ag
glassy carbon
electrode

8 pg/ml

0.25 – 250
ng/ml

30

Cardiactro
ponin1

Au

MCM-MCPE

0.5 ng/ml

0.8 – 5 ng/ml

31

PSA &
IL-6

MB-HRP-Ab2

AuNP -SPCE

0.23 pg/ml
0.30 pg/ml

0.225 – 5 pg/ml
0.30 – 20 pg/ml

32

PSA,
VEGF-D,
ERG &
IGF-1

Poly-HRP-Ab2

AuNP-SPCE

0.22 ± 0.05
zmol
0.341 ± 0.036
zmol
0.034 ± 0.002
zmol
0.083 ± 0.0012
zmol

0.06 -1044
fg/ml
0.04 – 7726
fg/ml
0.02 -149 fg/ml

37

0.01 – 52 fg/ml

The Rusling group has developed an ultrasensitive electrochemical immunoassay
strategies based on magnetic microbeads modified with large numbers of antibodies (~90,000)
and enzyme labels (~200,000) for multiplexed measurements of biomarker proteins.3,26,32,34-36
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The strategy also involves nanomaterial-modified or nanostructured electrode arrays housed in
simple fluidic devices to enable sandwich-type electrochemical ELISA with flow-through
amperometric detection. Electrode arrays are made by modifying the surfaces of electrodes (e.g.,
screen-printed carbon, gold film, etc.) with metal nanoparticles (AuNP) or carbon-based
nanomaterials to enhance electrochemical signal and antibodies for capture of antigens that are
labeled with magnetic bead bioconjugates (Table 1).
During immunoassays, electrode arrays are housed in simple polydimethylsiloxane
(PDMS)-based fluidic devices (volume <~100 µL), which are prepared from machined molds. A
simple syringe pump and manual injector are used to deliver reagents, washing solutions, and
magnetic bead bioconjugate labels to the electrode array. Due to the large numbers of antibodies
and enzymes on the magnetic beads along with the nanostructured electrode array surfaces,
detection limits for various proteins related to prostate and oral cancers have been reported in the
low fg/mL (femtogram per milliliters) range with this strategy. This is ~100-1000 times better
than traditional ELISA methods.32-36 For example, using this system, Chikkaveeraiah et al.
reported a multiplex detection of two biomarker proteins, prostate-specific antigen (PSA) and
interleukin-6 (IL-6) at a sub pg/ml level. Detection limits of 0.30 pg/ml and 0.23 pg/ml for IL-6
and PSA, respectively, were achieved with magnetic particles heavily conjugated with detection
antibodies (~9.0 x 104 active antibody) and enzyme labels (HRP) (~2.0 x 105 active HRP). This
report showed a great correlation with ELISA and an improvement on it given how the system
measured lower concentration at an analysis time of 1.15h (Table 1).32
In another study from Rusling’s group, Dhanapala et al. reported multiplex detection of
four biomarkers using a similar strategy. However, in place of magnetic beads, a commercially
available polymer modified with a large number of HRP enzymes was used to increase
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sensitivity. They reported, an unmatched sensitivity of sub-zeptomole and ultra-low detection
limit 0.08-0.22 zmol (zeptomole) when vascular endothelial growth factor -D (VEGF-D),
prostate-specific antigen (PSA), insulin-like growth factor-1 (IGF-1), and EST-related gene
protein (ERG) were measured in post-prostatectomy patient serum having low levels of analytes
(Table 1).37
Although Rusling’s group used simple PDMS-based microfluidic devices for
compatibility with low sample volumes (≤100 µl), the modular design of the system (i.e., twosided PDMS channel with top and bottom sides defined by hard acrylic plates secured together
with screws) requires manual positioning of electrodes, assembly and disassembly to complete
each assay.38 The dimensions of the PDMS channels are also typically too large (i.e., 1.5 mm
wide, 2.8 cm long) to fit most common definitions of microfluidics. As an alternative for simple
fabrication of microfluidic devices, Bishop et al. and others have recently explored the use of 3D
printing in making fluidic channels.39-47
3D-Printed Fluidic Devices
3D printing, also known as additive manufacturing, generally involves deposition, curing
or sintering of materials in successive layers to create a three-dimensional object from a model,
which can be prepared with the help of computer-aided design (CAD) software.48 Materials such
as ceramics, thermoplastics, metals, and graphene-based materials are some examples of
materials 3D printing technologies can print and can be in either liquid or powder form.38 In
recent years, 3D printing has found widespread use in research, aerospace, biomedical, art and
design, defense, etc.49
While the first 3D printing technology, referred to as stereolithography (SLA), was
commercialized by Charles Hull in the late 1980s, it has evolved especially rapidly over the past
19

decade and a half.50 There are currently at least eighteen 3D printing methods that employ a host
of diverse printing materials.43 These have been cataloged into seven groups according to
Standard F2792 of the American Society for Testing and Materials (ASTMs).51 SLA and fused
deposition modeling (FDM) are some examples of available printing technologies with the most
cost-effective desktop printers with a price range of less than one hundred to a few thousand
dollars.38 In SLA, a light source (e.g., a laser or projector lamp) cures a photosensitive resin,
while FDM employs a heated nozzle to extrude and deposit thermoplastic filament.
While fluidic devices have been prepared with several 3D printing techniques, including SLA,
FDM, and polyjet (i.e., photocuring of jettable inks) technologies, SLA continues to be one of
the most promising techniques in printing truly microfluidic channels due to its relatively high
resolution43 and low cost compared to other methods.39

Stereolithography Printing Technique
SLA printers rely on vat photopolymerization mechanism for printing.49 In this
technique, a photosensitive resin is polymerized by a light source (e.g., laser, or light-emitting
diode or mercury vapor lamp in a projector). The system consists of a vat, or container for
photosensitive resins, a platform for deposition of cured resin layers, a positioning system for
moving the platform and vat between curing cycles, and a light source for curing the resin. The
resins used in SLA generally consist of (acrylate or epoxy) monomers, a photoinitiator (e.g.,
phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide), and an absorbing species (e.g., Sudan I) that
is used to regulate the incident light penetration depth.39 While some systems (including Hull’s
original design) employ lasers for curing, digital light processing (DLP) projectors equipped with
light emitting diodes have become much more common sources in recent years as such
projectors can cure each layer by a single exposure (Figure 3).
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Figure 3. Schematic representation of DLP based SLA technique
3D Printed Microfluidic Devices
Many researchers, including Bharhava et al.,52 Shallan et al.,53 and Fang et al.,54 have
successfully printed fluidic devices using low-cost commercially available resins and SLA-type
printers. However, fluidic devices prepared using SLA often have channels with cross-sectional
dimensions of 200 µm to 1000 µm, which are often considered too large for microfluidics and
have been instead deemed millifluidics. In this traditional SLA, printing resolution is based on
the laser spot size or pixel size of projected light source. It is often difficult to make truly
microfluidic devices using SLA due to overcuring of the resin that resides in the fluidic channel
during printing, which results in blockage of small channels.55
Recently Nordin’s group has demonstrated the combination of SLA-DLP printing
technique with custom-formulated resins can enable 3D printing of microfluidic devices with
high resolution (27 µm in X-Y plane, 1 mm increment in the Z axis). In one report, they
demonstrated that controlling the concentration of absorbing species and photoinitiator in
21

formulated resins limits light penetration during exposure which then makes it possible for the
source spectrum to be fully covered by the absorber’s spectrum and limits overcuring of resin in
small channels. Using these strategies, they have reported microfluidic channels with cross
sectional dimensions as low as 18 µm x 20 µm.39,41,42 While 3D printing of microfluidic devices
is not yet routine, SLA remains a promising candidate with proven capabilities in this regard.56
3D Printed Fluidic Device with Electrochemical Sensors
Over the years, the combination of electrochemical immunoassays with 3D-printed
fluidic devices has been of particular interest to researchers due to its potential for automation
and miniaturization for point-of-care and clinical use.21,22 Along these lines, researches have
explored several strategies for interfacing electrodes with 3D-printed fluidic devices.57
One recently reported strategy is the fully embedding electrodes into 3D printed devices.
For example, Castiaux et al.58, reported the use of polyjet printing to directly embed a platinum
black electrode and counter electrode into a fluidic device for the electrochemical detection of
nitric oxide. This printing process used a stacked printing technique. Separate layers of the
device is printed and depending on where electrodes will be embedded, the layers are stacked
together into a single device with electrodes embedded using epoxy. Although this approach of
directly embedding electrodes during printing process brings about a robust sense of ease and
transferability for electrochemical sensing, electrodes fabricated this way are not reusable and
polyjet printing technique is costly.
Another strategy that is gaining popularity is the use of FDM printers to fully print fluidic
devices that feature incorporated sample processing and sensing elements, including electrodes,
valves, and pumps, in one step.59 O’Neil et al.60 demonstrated the use of FDM printing technique
to successful print a single step electrochemical flow-cell which simultaneously incorporated
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graphene composite poly(lactic acid) electrode and poly (lactic acid) insulator during the printing
process. Although this approach is promising, FDM lacks resolution to prepare microfluidic
channels. Devices printed with these strategies often cannot be reused, and applications may be
limited due to challenges associated with modifying electrodes directly printed in the fluidic
device.
Another approach reported for 3D-printed electrochemical sensors is the modular
incorporation of reusable electrodes into 3D-printed fluidic devices. In this approach, openings
or ports are designed in the fluidic device so that electrodes, housed in commercially available or
3D-printed fittings, can be inserted into and removed from the fluidic channel as desired. With
this approach, electrodes can be polished and subsequently reused for electrochemical detection
after exposure to other analytes.46,47
Using this modular electrode incorporation strategy together with biosensing strategy
previously reported by Jim Rusling’s group, Abdulhamid reported successful detection of
S100B, a protein biomarker associated with skin cancer and brain injury.7 In his report, a lowcost graphite electrode modified with glutathione-capped gold nanoparticles was integrated into
an SLA-prepared 3D printed fluidic device (800 µm by 800 µm cross-section). The fluidic device
featured outlet and inlet threaded ports that allowed the injection of reagents in and out of the
channel and a central threaded port where the modified electrode for the electrochemical sensing
was integrated.
Research Aims
Current clinical measurement of biomarkers proteins requires considerable time and cost.
However, recent research has shown that these measurements can be done via a combination of
the low-cost 3D printed flow cell and low-maintenance electrochemical biosensors. To date, this
23

promising way of analyzing protein biomarkers has only been applied to protein biomarkers
associated with oral and prostate cancer.61,62 As a result, the main goal of this research is to
apply this strategy to develop a highly reliable biosensing system, that would be capable of
measuring multiple circulating biomarkers associated with Pediatric Soft Tissue Sarcoma
(PSTS).
PSTS are fast-growing, uncontrollable tumors, which make up about 7% of all infancy
tumors and is the sixth most common cancer disease in children.63 These are classified into the
rhabdomyosarcomas (RMS), which account for 4% of infancy tumors, and the nonrhabdomyosarcomas (nRMS) soft tissue sarcomas, which also constitute about another 3%.
Although PSTS account for 7% of childhood cancer, the overall 5-year survival rate is fairly
poor (10% to 30%)64 in patients with the metastatic diseases. Surgery is the most common
treatment method for soft tissue sarcomas at the early stage, and for the last or extreme tumor
stage radiation being employed. About 40% to 50% of children with soft tissue sarcoma
experience the re-occurrence of the disease, which is almost always deadly, despite good local
control.63 There has been no standard staging system reported for PSTS.
Due to the increasing number of molecular genetic alterations occurring in the tumor
(sarcomas), soft tissue tumors are also categorized into two groups. One exhibits genetic
modifications. Another one exhibits several compounded karyotypic abnormalities with no form.
Some serum biomarkers for sarcomas are recently reported, including creatine kinase MB,
cancer antigen 125 (CA 125), polysialylated neural cell adhesion molecule (PS-NCAM),
midkine (MK), and osteopontin (OPN).65
In a study conducted by Lucas et al., midkine levels in sera sample of patients with
embryonal pediatric tumors were compared to a vast number of children without the disease. The
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study was conducted in 215 children without the disease and 29 pediatric patients with
embryonal tumors consisting of rhabdomyosarcomas (5), nephroblastoma (14), and
neuroblastoma (10) using an ELISA test. They reported a significantly higher MK levels in
tumor patients, recording a mean concentration of 0.62 ng/ml than in patients without the disease
recording a median concentration of 0 ng/ml (0 ng/ml at 25th percentile and 0.31 ng/ml at 75th
percentile). From their research findings, patients with rhabdomyosarcoma showed elevated MK
concentration in the collected sera sample with concentration as high as 52 ng/ml (median 0.29
ng/ml).66
Bache et al. conducted a study to ascertain association of OPN levels with patients with
soft tissue sarcoma. In this study, serum sample of 93 soft tissue sarcoma patients were analyzed
with an ELISA assay. They confirmed the presence of OPN in these serum samples with a
median concentration of 704 ng/ml (184-2660 ng/ml). They also confirmed the OPN levels in
serum was associated with clinical parameters such as tumor size, tumor grade etc.67 The
efficient clinical applications of these serum biomarkers have not been reported yet. As more
advanced attempts are needed to prove the clinical role of serologic tests in this malignancy, the
recognition of distinctive serum signatures for PSTS may lay out important value to detection,
precise prognosis and assessment of disease or ailment, and progress of treatment.32
In working towards achieving this goal, low-cost graphite electrode arrays were modified
with commercially available antibodies of MK, OPN, and CA 125 and subsequently integrated
into 3D- printed flow cells developed in-house using a desktop 3D printer through previously
reported strategies by Bishop et al.40 and Adulhamid.7 The sandwich electrochemical
immunoassay was developed using previously reported strategies and experiences from
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Rusling’s group.3,13,32,34-36 With this new measurement system developed, it will enable the
analysis of human serum samples obtained from PSTS patients and controls via biorespository.
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CHAPTER 2. EXPERIMENTAL
Chemicals and Instrumentation
Duosets containing antigen, capture and biotinylated detection antibodies of protein CA
125, OPN, and MK as well as streptavidin-HRP and enzyme substrate for ELISA development
were obtained from R&D Systems. The duoset antibodies and antigens were also used for
development of electrochemical ELISA. ProMag 1 magnetic microbeads (mean diameter: 0.80
µm, density: 1.8g/cm3) were supplied by Bangs Laboratories, Inc. 1-ethyl-3-(3-dimethyl
aminopropyl) carbodiimide (EDC) and N-hydroxysuccinimide (NHS) (98+%) were purchased
from Alfa Aesar. Potassium ferricyanide, ferrocenemethanol, sodium lauryl sulfate (SLS), and
citric acid were obtained from Fisher Scientific. Potassium chloride, concentrated sulfuric acid,
hydroquinone (≥99%), poly (diallyl dimethylammonium chloride) (PDDA) (20 wt% in H2O),
hydrogen peroxide (30% wt in H2O), ABTS, and Tween-20 (0.06 mM @ 20-25 OC) were
purchased from Sigma-Aldrich. Bovine Serum Albumin (BSA) (diagnostic grade) was obtained
from Millipore. Sodium hydroxide and concentrated hydrochloric acid were obtained from
VWR. Potassium chloride, potassium phosphate monobasic, sodium phosphate dibasic, and
sodium chloride were procured from Acros Organics. Graphite pencil rod (HB, 0.5 mm dia., 60
mm long) was purchased from Walmart. Photopolymer B9R-4-Yellow resin was procured from
B9Creations. Deionized water was passed through a Millipore Synergy UV water purification
system to obtain 18.2 MΩ cm ultrapure water, which was used to prepare all solutions.

27

Printing of 3D Flow-through Device
Printing of the flow-through fluidic device was done according to previous reports.7,39
The fluidic device was designed using 123D Design CAD™ software (Autodesk) and fabricated
using a B9Creator v1.2 DLP projector-based SLA 3D printer.

Figure 4. Photographic representation of B9Creator 3D-printer and the printing process. A)
Picture of a DLP-based projector of 1.2v B9Creator B) A computerized representation of the
fluidic device fabricated with computer-aided design (CAD) software. C) Illustrated
representation of SLA printing with DLP-based projector during printing7

Fabrication of Electrode
Disk-shaped electrodes were made by integrating metal wires and graphite rods into
commercially available fittings as described previously.46,47 These electrode fittings can be
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incorporated into the 3D-printed fluidic device through threaded ports as in previous reports by
Bishop et al.39 and Erkal et al.40 Each fitting consisted of three working electrodes made using
pencil graphite rods, a reference electrode made from 0.25 mm diameter silver wire coated with
silver chloride, and a counter electrode fashioned from the barrel of an 16G stainless steel
needle. These electrodes were centered at the bottom of the fitting at equal distance to the ringshaped counter electrode which had the reference electrode placed inside it. The space between
the electrodes was filled with epoxy. After curing, the epoxy was polished to expose the
electrodes (Figure 5).

Figure 5. A complete photographic representation of the electrode fabrication process. A)
Individual electrodes with commercially available fitting. B) integrated electrodes into the
fitting. C) Image of fitting from below D) incorporation of fitted electrodes into a 3-D printed
microfluidic device
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For carbon working electrodes, graphite pencil rods (0.5 mm diameter) were connected to
copper wire by using a conductive silver paste and subsequently insulated using Teflon tape to
avoid shorts to neighboring electrodes. The ring-shaped counter electrode was prepared made
from the barrel of a stainless-steel needle. The reference electrode was fabricated by wrapping a
silver wire around the copper and gluing them together using a conductive paste. The reference
electrode was then insulated using Teflon tape to cover the silver wire-copper wire junction to
prevent coming into contact with the counter electrode when placed in the barrel of the stainlesssteel needle. Prior to the insertion of all individual electrodes into the fitting, the resistance of the
electrodes was checked using a multimeter. The silver paste provided electrical connection to the
electrodes with a low resistance of 0.9 Ω. After insertion of electrodes into fittings and polishing,
resistance was checked again as negligent manipulation of electrodes can cause disconnection or
electrical shorting. The conductivity of the electrodes was checked by hooking both ends of the
electrode to a multimeter and to another electrode to ensure the electrodes are not in contact with
each other. The copper wire provides connection of the electrode to the electrochemical
instrument for measurements.
Electrochemical Measurement of Fabricated Electrodes
After the fabrication of electrode fittings, electrode polishing and conductivity checks,
the reference electrode was coated with silver chloride to provide the system with a quasireference electrode.46,68 This was done by placing the assembled electrode fitting in a 3.5 M KCl
solution and connecting the reference electrode lead to the anodic part of a 9 V battery using 1.0
MΩ resistor embedded copper wire. The cathodic part of the battery was connected to silver
chloride coated silver wire place in the same 3.5 M KCl solution to complete the circuit. This
was allowed to stand for a minimum of thirty minutes until silver wire appeared gray after which
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the open-circuit potential of the wire was measured in 1 M KCl against a commercial CH
instrument Ag/AgCl reference electrode (1 M KCl filling solution). Open circuit potentials were
found to be between 0 to 9 mV, indicating that silver chloride was successfully deposited on the
silver wires. To evaluate the performance of the electrode fittings, cyclic voltammetry was
performed using 8-channel CHI1040C electrochemical analyzer. Amperometry was performed
with the CHI1040C to carry out the electrochemical immunoassay.
Electrochemical Immunoassay
The electrochemical immunoassay strategy was adapted from previous work and reports
by Prof. Jim Rusling’s group,3,13,33-36 which are based on capture antibody-modified glutathione
(GSH)-capped gold nanoparticle (AuNP)-decorated screen-printed carbon electrodes and a
magnetic microbeads that are heavily labeled with an enzyme (HRP) and detection antibody for
biomarker protein isolation and signal generation. The same general strategy is employed here,
except electrode fittings and graphite working electrode arrays are employed in place of screenprinted electrodes, and a 3D-printed fluidic device is used in place of simple PDMS-based fluidic
channels.
The electrode fitting featuring antibody-modified GSH-AuNP graphite working
electrodes is integrated into the 3D-printed fluidic device. The magnetic microbeads are
functionalized with streptavidin, which enables the attachment of commercially available
biotinylated antibodies and enzyme labels for electrochemical detection. Sample containing all
the three biomarkers (CA 125, OPN, MK) is exposed to labeled magnetic bead where each
specific detection antibody isolates its biomarker (CA 125, OPN, MK) of interest. The labeled
biomarker is introduced onto the antibody-coated nanostructured electrode via an injection
system, where the specific capture antibody on the electrodes forms a sandwich link with its
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specific biomarker. Electrochemical detection is achieved by using hydrogen peroxide to activate
the iron (III) center of the HRP label into a ferryloxy form, which reacts with an oxidizable
species (e.g., hydroquinone) to produce an electrochemically reducible product (e.g.,
benzoquinone). A signal is generated in the form of current as the benzoquinone (formed from
the reaction of hydroquinone with the activated enzyme) is electrochemically reduced back to
hydroquinone when an appropriate potential is applied to the working electrode (Figure 6).

Figure 6. Illustration of the electrochemical immunoassay sensing strategy.A) Antibody modified
GHS-AuNP graphite electrode. B) Magnetic bead functionalized with streptavidin to enable the
covalent attachment of detection antibody and enzyme (HRP) label. C) Isolation of biomarkers
with the magnetic bead bioconjugate. D) introduction of labeled biomarker onto the electrode
surface for signal generation. E) Achievement of electrochemical detection through hydrogen
peroxide oxidation of HRP and subsequent signal development by reduction of benzoquinone to
hydroquinone. F) Set up for the biosensing system involving syringe pump for introducing
reagent in the system, an injector for labeled biomarker conjugate introduction onto the electrode
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surface placed in the fluidic device, and electrochemical analyzer for a signal potential
generation

Electrode Modification with GSH-AuNP and Capture Antibody
Glutathione capped gold nanoparticles (diameter ~4 nm) were synthesized and
characterized according to previously reported protocols.32,36 Gold nanoparticles were deposited
onto the graphite electrode via layer-by-layer electrostatic adsorption using a cationic polymer
PDDA (Figure 7) followed by attachment of capture antibody through EDC/NHS amide bond
formation. After deposition of GSH-AuNP onto the electrodes, cyclic voltammetry was
performed in 500 mM sulfuric acid at a potential of -0.2 V to 1.5 V at 100 mV/s for 6 sweep
segments to confirm presence of AuNPs.

Figure 7. Layer-by-layer electrostatic adsorption modification of electrode with GSH-AuNP and
capture antibody
Fabricated electrodes were rinsed with purified water, dried with nitrogen gas after which
~0.5 µl of 2 mg/ml PDDA was deposited and allowed to sit overnight. After performing CV,
washing, and drying with nitrogen gas, a 0.5 µl of GSH-AuNP was drop cast onto the electrodes
and allowed to sit overnight. A mixture of 0.5 µl EDC/NHS (~374 mM/~750 mM) was
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deposited on the AuNP modified electrode and allowed to sit for 10 minutes after rinsing and
drying the electrode. This was done to activate the carboxylate groups of glutathione for the
attachment of capture antibody. Capture antibodies were prepared to the desired concentration.
0.3 µl of capture antibodies were carefully placed on each working electrode in the fitting,
making sure that different capture antibody solution does not mix and keeping track of which
electrodes have been modified with which antibody. Antibody-GSH-AuNP modified electrodes
were then covered and incubated in the fridge overnight.
Preparation of Magnetic Bead-Antibody (Ab2)-Enzyme (HRP) Bioconjugate
Following previous works and reports published by Malhotra et al.26, Chikkaveeraiah et
al.32, Krause et al. 36, and guidance from the manufacturer of magnetic beads (MBs) employed in
these studies69, HRP-MB-antibody (Ab2) bioconjugates were made by first modifying magnetic
beads with antibodies, followed by HRP. Briefly, 20 µl streptavidin-coated MBs (0.2 mg) were
washed three times using 200 µl of 0.1 M phosphate buffer saline (PBS, pH 7.4). The MB
suspension was vortexed and separated from wash buffer (PBS) with the aid of a 3D- printed
tube holder magnetic bead separator. The separated pellet was resuspended in a 400 µl wash
buffer to give a MB concentration of 0.5 mg/ml after the final wash. The HRP-MB-Ab2
bioconjugate was optimized by varying the concentrations of Ab2 (20 µl, 10 µl, 5 µl of 6 µg/ml)
while amounts of HRP (15 µl of 0.25 mg/ml) and MB (50 µg) were constant. First, 100 µl of MB
was modified with the varying volumes of Ab2. For consistency, the volumes were brought to a
total of 120 µl with PBS, votexed and placed on a rotator of 45 mins. MB-AB2 were resuspended
in 100 µl PBS after washing (3x) and vortexing. After modification of MB with Ab2, MB-Ab2
was mixed with 15 µl of HRP , vortexed and placed on a rotator (Figure 8) for 45 minutes. Beads
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were separated from the solution and washed 3x with 100 µl of PBS and resuspended to a final
concentration of 0.5 mg/ml in 0.1 M PBS

Figure 8. Illustration and photographic representation of the bioconjugation process. A)
preparation process of MB-HRP-AB2 bioconjugate. Mixing of MB with reagent with vortex A)
followed by separation of MB from wash buffer using magnetic separator B). HRP and AB2 bind
together on MB when placed on rotator D) for some time
Characterization of HRP Activity on Bioconjugate Using ABTS Assay
Active HRP content on modified magnetic bead was measured by performing an 2,2’azino-bis (3- ethylbenzothiazoline-6-sulphonic acid) (ABTS) assay using an optical density plate
reader. HRP standards ranging from 2 ng/ml to 100 ng/ml were made by diluting stock biotinHRP solution (2.5 mg/ml) in a 0.01 M PBS. Magnetic bead bioconjugates were diluted 160x
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with 0.1 M PBS and 10 µl of each standard and samples were placed in the wells of the plate. To
this, 150 µl of 1mg/ml ABTS in 100 mM phosphate citrate buffer (pH 5.0) with 0.03% hydrogen
peroxide was added. This was incubated at room temperature for 30 minutes. To each well
containing sample and standards, 100 µl of 0.6% SDS/SLS solution was added to stop reaction.
With a recommended wavelength of 420 nm and a blank solution consisting of 150 µl
phosphate-citrate in 100 µl 0.6% SDS/SLS, optical density measurement was taken at 420 nm
wavelength with a background wavelength set at 600 nm.
Isolation And Labeling of Biomarker
For isolation and labeling of biomarker proteins from the sample during electrochemical
immunoassays, three sets of HRP-MB-Ab2 bioconjugates were prepared as described above
using different antibodies ( CA 125, OPN, MK) since each biomarker requires a different
detection antibody. Magnetic beads with different Ab2 labels were mixed, vortexed, washed
separated, and resuspended in 0.1 M PBS to a final concentration of 0.5 mg/ml. To MB
biconjugates, 30 µl of the solution was added to 10 µl of sample or control (PBS). The solution
was then vortexed and placed on a rotator for 20 minutes at 400 RPM. After completion of
labeling incubation period, the liquid portion of the solution was separated from magnetic beads
by washing it 3x with 0.1 M PBS as described above. Beads were finally resuspended in 60 µl
PBS and kept in the fridge or ice prior to analysis.
Flow-Injection System
Prior to electrochemical signal development, the antibody-modified electrode was
obtained and inserted into the fluidic device while the labeled biomarker bioconjugate was left to
incubate. The obtained electrode was rinsed in 0.1% Bovine Serum Albumin (BSA) in PBS. This
was done to reduce non-specific binding on the electrode and in the flow cell. The electrode was
36

inserted into the central port of the 3D printed flow cell. This was carefully done as
overtightening could break and destroy the flow cell. To improve sealing with into 3D printed
threaded port, the threaded part of the electrode fitting was wrapped with Teflon tape. An inlet
tubing was inserted into one of the threaded ports which had been secured with commercially
available fitting. The tubing was connected to the outlet of a manual injector (Rheodyne, LLC)
that featured a 20 µl sample loop and inlet connected to a syringe pump (New Era Systems) to
complete the flow-injection system. This system (figure 9) is designed to aid in the delivery of
reagents, samples, and control onto the electrode surface through the channel for electrochemical
measurement. An optimized flow rate of 100 µl/min was used for amperometry.

Figure 9. Photographs of the flow-injection system. A) Photograph of the syringe pump at 100
µl/min. B) Photograph of an injector connected to a fluidic device with incorporated electrode
through the inlet tubing
Capture of Labeled Biomarker and Electrochemical Signal Development
For capture of antigen-Ab2-MB-HRP onto electrodes, 60 µl of 1% BSA in PBS was
loaded and injected into the sample loop with 0.05% Tween-20 in PBS drawn in a syringe to
facilitate the flow of BSA onto the electrode surface and through the flow-cell channel. This was
done to reduce non-specific binding in the flow cell and on the electrode surface. Upon the
arrival of BSA on the electrode surface after 40 seconds, the flow was stopped to allow
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incubation of BSA on the electrode surface for 5 minutes. The flow was resumed and, with the
injector lever in the load position, 60 µl of beads were carefully loaded into the sample loop.
The beads were injected into the fluidic device at a rate of 100 µl/min by moving the lever of the
manual injector into the inject position. The flow was stopped once beads reached the electrode
and incubation carried out under stopped-flow for 10 minutes. The flow was resumed at 10
µl/min for 8 minutes followed by 100 µl/min for 3 minutes to ensure enough time for beads to
bind and completely remove excess beads.
For signal development, 1.0 mM hydroquinone solution in the syringe was allowed to
flow through the system at 100 ul/min for about 2 minutes. An appropriate potential was applied
to the electrode using an i-t method in the electrochemical analyzer software. After the decay of
background current to near zero for about 100 seconds, a mixture of 100 µM hydrogen peroxide
in 1 mM hydroquinone was carefully loaded into the sample loop and injected to activate HRP
label present on magnetic beads. Signal which is proportional to the concentration of biomarkers
present in the sample was provided by the reduction of benzoquinone (oxidized hydroquinone)
back to hydroquinone.
Enzyme-Linked Immunosorbent Assay Measurement
ELISA measurement was done based on protocol provided by the Duoset manufacturer
(R&D Systems). Capture antibody was diluted to working concentrations using PBS. A 96-well
microtiter plate was coated with 100 µl of the capture antibody, sealed and allowed to incubate
overnight at room temperature. Wells were then washed with 400 µl wash buffer and plate
blocked with 300 µl reagent diluent to prevent non-specific binding for 1 hour. Aspiration and
washing were performed after plate blocking process.
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To each well of the titer plate, 100 µl of sample or standards in reagent diluent was
added. The plate was then covered with an adhesive strip and allowed to incubate for 2 hours.
Aspiration and washing step were repeated after the 2 hours incubation period. To each well, 100
µl of detection antibody, diluted to working concentration in reagent diluent was added, covered,
and let to incubate for 2 hours. Aspiration and washing steps were repeated. Following this, 100
µl of streptavidin HRP was added, plate covered and incubated for 20 minutes. Aspiration and
washing steps were performed which followed addition of 100 µl substrate solution, incubated
away from light for 20 minutes. Finally, a 50 µl stopping solution was added to the substrate
solution and gently mixed thoroughly for optical measurement at a 450 nm wavelength using 540
nm wavelength as background correction.
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CHAPTER 3. RESULTS AND DISCUSSIONS
Electrode Characterization
Electrochemical signal is largely dependent on the activity or behavior of the electrode.
The electrochemical behavior of pencil graphite working electrodes was evaluated using cyclic
voltammetry. Electrode fittings were placed in a solution of 0.1 M KCl (supporting electrolyte)
with 0.5 mM ferrocene methanol (FcMeOH) as the redox probe. In this solution, a pair of peaks
centered at 198.0 ± 5.0 mV (n=20) vs. Ag/AgCl reference electrode was observed, which is
consistent with the one-electron oxidation of ferrocenemethanol and subsequent reduction. The
separation between the anodic and cathodic peaks was found to be 65.0 mV, ranging from 55mV
to 77.0 mV. Although the peak separation is slightly higher than the expected Nerst faradaic
potential (59 mV) for a one electron reversible redox system, the obtained value of 65 mV is in
good agreement with reported values for other carbon-based electrodes for a reversible electron
transfer system,7,70-77 which confirms the pencil graphite working electrodes are suitable for
electroanalytical measurements.
Pencil graphite working electrodes are composed of a mixture of graphite, clay, and a
polymeric binder. The ratio and distribution of these components can vary at the electrode
surface, which can affect faradaic current measurements.70,72-75 Therefore, the electroactive
surface area (i.e., the area of the electrode that can participate in electron-transfer reactions; also
known as the real surface area) of each electrode was determined by applying the Anson
equation76 (Eqn. 1) to chronocoulometric data obtained from the oxidation of 0.5 mM ferrocene
methanol in 0.1 M KCl at an applied potential of 350 mV.
𝐷𝑡

Q = Qdl + Qads + 2nFAeC ( 𝜋 )1/2
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(1)

where Q is the charge (in C), Qdl and Qads are charges associated with double-layer
charging and Faradaic reactions of adsorbed species, n is the number of electrons transferred
during electrochemical redox reaction, F is Faraday’s constant (96,485 C/mol), Ae is the
electroactive surface area (in cm2), C is the concentration of redox probe (i.e., FcMeOH) (in
mol/cm3), and D is the diffusion coefficient of the redox probe (7.80 x 10-6 cm2/sec).77
Using equation 1 the average electroactive surface area based on twenty electrodes was
4.5 (± 2.4) x 10-3 cm2 (n=20). The geometric surface area that is expected for graphite pencil with
0.5 mm diameter and 60 mm long is 2 x 10-3 cm2. The electroactive surface areas of pencil
graphite electrodes have generally been reported as larger than their corresponding geometric
areas (e.g., 0.255 cm2 for a 0.5 mm HB-type pencil78, 3.1 x 10-3 cm2 for 0.5 mm pencil7). Large
electroactive surface areas help facilitate measurement of low concentrations of analytes.79 The
variations observed between the electroactive surface area of the electrodes and the geometric
area may be attributed to the roughness of the electrode surface and variations the cross-sectional
shapes due to the positioning of electrodes in fitting during electrode fabrication. Current
generated at each electrode was normalized by the electroactive surface area (Figure 10 C-D) to
account for differences in response that can be attributed to differences in electrode size.
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Figure 10. Electrode characterization and surface area estimation. A) Illustrated CV response for
an electrode in a fitting showing redox peak response centered at 198.0 mV vs Ag/AgCl with
peak separation of 65 mV. B) Illustrated chronocoulometric response for electrode showing the
slope used in the Anson’s Equation. C) CVs of raw currents of 3 working electrodes in a fitting.
D) CVs of current density of 3 working electrodes in a fitting
Since electrochemical sensing during immunoassay experiments is performed in a 3Dprinted fluidic device, the electrochemical behavior of the electrode fitting in the flow-cell was
ascertained using CV and compared to CV measurement obtained for the electrode fitting when
placed in a beaker. Using hydroquinone (since it is the electrochemical oxidizable species for
sensing) as the redox probe, CV measurement was repeated for electrode in and out the fluidic
device to compare their electrochemical response.
The results obtained for both in and out the fluidic channel did not show any significant
differences in the peak current and peak position for electrode (Figure 11). This confirmed that
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electrochemical sensing can be reliably and successfully performed in the 3D printed fluidic
device with low-cost graphite electrodes incorporated.

Figure 11. CV responses of electrode fitting inside and outside the fluidic channel towards a 1.0
mM hydroquinone redox at a scan rate of 100 mV/s. Arrows indicate the scan direction
Flow-through Amperometry
The sensing system (Figure 9) involves the introduction of reagents, samples into the fluidic
device, incubation periods and washing step. Therefore, it is of extreme importance to establish
when reagents reach the electrode surface in the flow cell upon injection. A 20 µl mixture of
potassium ferricyanide K3[Fe (CN)6] (1.0 mM) in 0.1 M KCl (supporting electrolyte) was
injected under a 100 µl/min flowrate at a constant potential at which potassium ferricyanide is
reduced to potassium ferrocyanide (0 V vs. Ag/AgCl). Once the redox probe reached the
electrode surface, a peak-shaped response appeared after an average time of 40.15 (± 0.75) s of
injection (Figure 12). This generated an average current of 131 (± 3.02) nA and a peak area of
3.021 (± 0.068) µC. This implies that, flow injection could be stopped at ~40 s to allow reagents
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and reactions such as non-specific binding, washing steps and incubation of MB bioconjugate to
take place on electrode surface to ensure maximum binding of analyte to capture antibodies on
the electrode surface.

Figure 12. Flow-through amperometric signal for a 20 µl of 1 mM ferricyanide in 0.1 M KCl
injected at 300 sec, 500 sec, and 800 sec under a 100 µL/min flow of 0.1 M KCl at a constant 0
V potential vs. Ag/AgCl
Electrode Modification and Characterization
Electrochemical immunoassay was developed by modifying the electrode surface with
glutathione-capped gold nanoparticle (GSH-AuNP) and capture antibody. GSH-AuNPs were
prepared and particle size estimated based on previous reports by Rusling et al. 32,34,35 The
position of the surface plasmon resonance peak (Aspr) at 515 nm in the UV-Vis spectrum (Figure
13) is consistent with previous reports indicating the particles to be <25 nm in diameter.80 In
order to estimate particle size that is less than 25 nm by UV-Vis, the ratio of the absorbance at
the SPR peak (i.e., Aspr) to absorbance at a 450 nm (A450) is used as reported by Haiss et al.80
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From the particles made, the ratio of Aspr to A450 was dtermined to be 1.19 and this corresponds
to 4 nm.

Figure 13. Peak position at 515 nm for a 4 nm GSH-AuNP on a UV-Vis spectrum
Using a layer-by-layer electrostatic adsorption strategy previoulsy employed for pyrolytic
graphite81 and screen-printed carbon32,35,77 electrodes, GSH-AuNPs were adsorbed onto pencil
graphite with the aid of a cationic PDDA polymer interlayer.81 To confirm the successful
deposition of AuNP on the electrode, CVs in 0.5 M sulfuric acid were performed on unmodified
and modified electrodes in the potential window of -0.2 V to +1.5 V vs. Ag/AgCl. Within this
range, surface gold is oxidized to gold oxide and on the return scan, reduced back to gold
according to the following half-reaction7:
3H2O + 2Au

Au2O3 + 6H+ + 6e-

An anodic (oxidation) peak positioned at 1.2 V and a cathodic (reduction) peak at 0.65 V
indicated the successful depostion of AuNP. This was compared to CVs of unmodified and
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PDDA modified electrodes which showed no significant peaks (Figure 14). A mixture of
EDC/NHS was used to activate the carboxylate functional groups on the AuNP in order to form
amide bonds with amine groups on the antibodies (CA 125, OPN, MK).

Figure 14. CVs at scan rate of 100 mV/s of bare, PDDA and AuNP-modified electrodes in 0.5 M
H2SO4. Arrow shows the beginning of scan
Ab2-MB- Hrp Bioconjugation and Characterization
For the optimization of HRP-MB- Ab2 bioconjugate, the washed magnetic beads was
portioned into four separate microcentrifuge tubes (0.05 mg MB per tube). To each centrifuge
tube, varied amounts (0.12, 0.06, 0.03 µg) of biotinylated detection antibody was added. For
consistency, all biotin-IgG detection antibody was brought to a total volume of 120 µl by adding
PBS. A constant amountof HRP (3.75 µg) was added to all the Ab2-MB sololution, washed and
resuspended at a final concentration of 0.5mg/ml in 0.1 M PBS.
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To determine the amount of active HRP per magnetic bead, an ABTS assay was
performed at an absorbance of 420 nm using standards concentration of HRP ranging 0 ng/ml to
100 ng/ml (Figure 15) to develop a calibration curve (Figure 16).

Figure 15. Microtitre plate showing concentrations (0 ng/ml to 100 ng/ml) of standard HRP with
a mixture of 1 mg/ml ABTS in 100 mM phosphate citrate buffer and 0.03% hydrogen peroxide.
Arrow direction indicate lower concentration to higher concentration

Figure 16. Calibration curve of HRP using ABTS assay

47

It was observed that there was a decrease in active HRP for bioconjugate with increased
antibody on the MB during immobilization step (Figure 17). The estimated active HRP per MB
particle was calculated to be in a range of ~20,000 to ~100,000. The range of active HRP
obtained is in very close agreement with previously reported active HRP (~2 x 105) by Rusling et
al .34,35,36

Figure 17. Active HRP per magnetic bead during functionalization
Signal is enhanced by the amount of HRP present on the magnetic bead, while a large
amount of Ab2 labels is necessary for effective capture of low concentrations of antigens.82
Therefore, it is important to have an appropriate ratio of HRP to Ab2 to enhance signal and push
detection limit low. With no antibody on the MB (0 µg/mg MB), maximum binding of HRP was
observed with ~100,000 active HRP. This had no significant difference when 0.6 µg of antibody
were immobilized on the MB during bioconjugation and little HRP present (~20,000 active
HRP) when amount of the antibody per magnetic bead was increased to 2.4 µg/ml MB. Having
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observed this, 1.2 µg of antibody per mg MB was selected for the electrochemical assay since
there were enough antibody to HRP present on MB.
Enzyme-Linked Immunosorbent Assay
Prior to the electrochemical immunoassay development, traditional ELISAs were
performed on protein standards and pooled human serum samples. This was done to ascertain the
level of quality of the commercially available duoset antibodies, which were also used to modify
electrodes and magnetic beads for electrochemical immunoassays. Using a standard
concentration ranging from 78.1 -5000 pg/ml for MK, 62.5 – 4000 pg/ml for OPN and 31.3 –
2000 pg/ml for CA 125, a four-parameter log fit (4-PL) calibration curves were generated for all
biomarkers (Figure 18-20) with R2 values of 0.998, 0.999, and 1 for MK, OPN, CA125
respectively.

Figure 18. Illustrated calibration curve for standard Cancer Antigen concentrations ranging from
31.3 – 2000 pg/ml
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Figure 19. Illustrated calibration curve for standard Midkine concentrations ranging from 78.1 –
5000 pg/ml

Figure 20. Illustrated calibration curve for standard Osteopontin concentrations ranging from
62.5 – 4000 pg/ml
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To determine if the matrix of the human pooled serum sample is interfering or has any
effects on the ability of the capture and detection antibody to bind with antigen, a spike and
recovery test was performed. By spiking a known concentration of the various biomarker
standards into the serum sample, percentage recovery ranged between 87.91 % to 106.91 % for
CA 125, 82.58 % to 103.70 % for OPN and 88.52% to 98.09% for MK. In performing this type
of assay (ELISA), measurement is said to have little or no matrix interference if percentage
recovery is in the range 80 – 120.83 This showed that the antibodies were in good condition and
suitable for the electrochemical assay.
Table 2. Concentration and % Recovery for CA 125 Biomarker. Measured Concentration of
Unspiked Serum was 247.9 (± 8.6), n=3
Spiked conc. (pg/ml)

Mean measured spiked conc.

Mean % Recovery / (±SD)

(pg/ml) / (±SD)
70

62 (± 13)

88 (± 22)

350

374 (± 32)

106.9 (± 8.6)

700

672 (± 88)

96 (± 14)

1400

1335 (± 99)

95.3 (± 7.4)

Table 3. Concentration and % Recovery for OPN Biomarker. Measured Concentration of
Unspiked Serum was 1886.1 (± 13.9), n=3
Spiked conc. (pg/ml)

Mean measured spiked conc.

Mean % Recovery / (±SD)

(pg/ml) / (±SD)
100

96 (± 24)

96 (± 25)

750

620(± 57)

82.6 (± 9.2)

1500

1453 (± 104)

96.9 (± 7.2)
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3000

3111 (± 113)

103.7 (± 3.6)

Table 4. Concentration and % Recovery for MK Biomarker. Measured Concentration of
Unspiked Serum was 3557.6 (± 31.3), n=3
Spiked conc. (pg/ml)

Mean measured spiked conc.

Mean % Recovery / (±SD)

(pg/ml) / (±SD)
80

79 (± 20)

98 (± 25)

800

710 (± 36)

88.5(± 5.1)

1600

1473 (± 50)

92.1 (± 3.4)

3200

3069 (± 53)

95.9 (± 1.7)

Concentrations obtained for the various biomarkers were in range with concentrations
reported in literature.66,67

Electrochemical Immunoassay Signal Development
For electrochemical immunoassay development, standard mixtures of the three
biomarkers (MK, OPN, CA 125) were introduced to a mixture of HRP-MB-Ab2 bioconjugates.
After incubation to label biomarker proteins with corresponding bioconjugate and subsequent
washing to remove other proteins and materials, the bioconjugate-labeled protein mixture was
injected into the flow-through system and onto the electrodes for capture and detection. A
mixture of hydrogen peroxide and hydroquinone is introduced into the system to activate Fe (III)
center of the HRP on the bead via oxidation. This activated HRP in turns oxidizes the
hydroquinone into benzoquinone. Therefore, for electrochemical signal to be generated, a
constant potential at which benzoquinone is reduced back to hydroquinone must be applied.
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To determine the potential for the reduction of benzoquinone back to hydroquinone, CV
measurements were taken in 1mM hydroquinone with phosphate-buffered saline as the
supporting electrolyte. Hydroquinone was first oxidized to benzoquinone electrochemically and
on the return scan, reduced back to hydroquinone (Figure 21). A pair of redox peaks centered at 30 mV with a peak separation of 64 mV were obtained from the voltammogram. From the
voltammogram obtained, a more negative potential of -0.20 V was selected for the
electrochemical signal development. This is due to the fact that, at that potential all the
benzoquinone had been completely reduced back to hydroquinone and so to avoid the onset of
current from other possible reactions while achieving a complete reduction of benzoquinone
generated from the enzymatic reaction, a potential of -0.20 V is appropriate to use.

Figure 21. CV in a 3D-printed fluidic device for a 1.0 mM hydroquinone solution in 0.1 M PBS
at a 100 mV/s flowrate. Beginning of the scan is shown by the blue arrow. The red arrow shows
the potential (- 0.20 V vs. Ag/AgCl) used in the amperometric detection of reduced
benzoquinone
The fundamental principle for electrochemical signal development is the reduction of
enzyme-generated benzoquinone to hydroquinone. There it is possible to obtain a false positive
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result for signal development if the hydrogen peroxide used in the activation of Fe (III) of the
enzyme (HRP) can directly oxidized hydroquinone to benzoquinone or oxidize it
electrocatalytically with the presence of AuNP on the electrode surface, since hydrogen peroxide
is an oxidizing agent.
To confirm that signal generation is directly from the reduction of enzyme-generated
benzoquinone (i.e., presence of HRP-MB-Ab2), two amperometric detection was performed,
where one test had HRP-MB-Ab2 present and the other with no bioconjugate present (just pure
water). Amperometric signal was generated only for the test with HRP-MB-Ab2 (Figure 22).
This confirmed that HRP-MB-Ab2 is necessary for the oxidation of hydroquinone to
benzoquinone and that hydrogen peroxide alone or with AuNP present, would not be able to
oxide hydroquinone to benzoquinone.

Figure 22. Amperometric response generated to compare in the absence and presence of Ab2MB-hrp bioconjugates. For Control signal generation, electrode was exposed without CA 125
and MB bioconjugates (only purified water). For Sample, electrode was exposed to 0.31 pg/ml
sample conjugated with MB bioconjugate. Signal was developed by injecting a 1 mM
hydroquinone with 0.1 mM H2O2 at a flowrate of 100 µL/min. Arrow indicates sample
injection time at an applied potential of -0.20 V vs. Ag/AgCl
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To demonstrate that immunoassay signal is related to the concentration of antigen,
mixtures containing MB bioconjugates for the 3 different proteins (CA 125, OPN, and MK) were
added to standard solutions containing 0 pg/mL (control), low concentrations (100x lower than
lowest reported concentration for commercial ELISA), and moderate concentrations (equal to the
lowest reported concentration for commercial ELISA) of CA 125, OPN, and MK proteins.
Mixture of 100 µM hydrogen peroxide in 1 mM hydroquinone was subsequently injected into
the system which generated an amperometric signal (Figure 23).
From the obtained signals, it can be noticed that controls exhibited a non-zero signal
although controls had no analyte present. This is due to non-specific (NSB) binding of Hrp-MBAb2 bioconjugate on the electrode surface although appropriate steps were taken to minimize
NSB. Amperometric signal increased as concentrations of the biomarkers increased with all
biomarkers exhibiting amperometric signals for concentrations that were 100 times lower than
the lowest reported concentration for commercial ELISA. Lower analyte concentrations (0.313
pg/ml – 0.781 pg/ml) generated signals ranging between 7.89 – 9.64 µA/cm2 than their controls
while higher concentrations (31.3 pg/ml – 78.1 pg/ml) generated signals ranging 14.69 - 18.16
µA/cm2. Although controls generated signals due to NSB, lower concentrations generated signals
that are ~ 3.2 times higher than their controls with signals being qualitatively reproducible.
Therefore, these results indicate that, multiple biomarkers than be successfully detected using
low-cost graphite electrode incorporated into 3D printed fluidic device. It is also capable of
detecting analytes concentrations that are 100 times lower than the lower limits of ELISA tests.
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Figure 23. Simultaneous amperometric response for three biomarker detections.A) Response for
MK concentrations at 0 pg/ml (control), 0.781 pg/ml (100x lower than LOD of ELISA), 78.1
pg/ml (LOD for ELISA) B) Amperometric signal for OPN concentrations at 0 pg/ml (control),
0.625 pg/ml (100x lower than LOD of ELISA), 62.5 pg/ml (LOD for ELISA) C) Response for
CA 125 at concentrations 0 pg/ml (control), 0.313 pg/ml (100x lower than LOD of ELISA), 31.3
pg/ml (LOD for ELISA)
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CHAPTER 4. CONCLUSION AND FUTURE WORKS
Advances in research and the use of convenient and effective way to isolate, characterize and
detect biomarker proteins has led to a strong emphasis on the development of biomarker panels.
However, the most commonly used ELISA technique lacks the ability to detect multiple
biomarkers. Sophisticated technologies used in multiple biomarker analysis are rather expensive
and often require proprietary reagents. Since multiplex protein biomarker measurements requires
large-scale validation studies, there is serious need for simpler, lower cost alternatives.
Electrochemical measurements are well-suited for measuring multiple biomarker proteins due to
its low-cost, lack of required maintenance, compatibility with multiple measurements and
potential for miniaturization.
A combination of electrochemical measurement with 3D printed fluidic device has posed
as an alternative platform for multiple biomarkers sensing due to the low cost, ease of operation
and fast design to object workflow associated with 3D printing material. In this research, we
have exhibited that low cost graphite electrodes modularly incorporated into a 3D printed fluidic
device can be used to successfully detect three biomarkers (CA 125, MK, OPN) associated with
PSTS electrochemically.
The 3D fluidic device was printed based on dimensions previous report by Bishop et al.
and Abdulhamid. Modularly incorporated electrodes were electrochemically characterize using
FcMeOH redox probe to ascertain the functionality and reliable of the electrodes for
electrochemical measurements which was subsequently modified with AuNP and capture
antibodies. By optimizing HRP-MB-Ab2 bioconjugate, and appropriate ratio was used to isolate
biomarkers for the sensing strategy. Using an optimized amperometric potential of 0.20 V, a
simultaneous electrochemical detection of the three biomarker proteins was achieved with the
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antigen-bioconjugate serving as a platform for the electrochemical oxidation and reduction of
hydroquinone at a 100 µl/min flow-rate.
While this system has successfully enabled detection of multiple biomarker proteins
concentrations that are 100x lower than what is typically analyzed by ELISA, it is important to
generate a calibration curve using standard concentrations to determine the sensitivity, limit of
detection and dynamic range of the system to which will help measure real human PSTS
samples. Although commercially available protein antibodies are proven to be effective in the
development of sandwich type assays, some weak binding of analyte and non-target proteins
may generate signal, therefore it is important also to evaluate parameters such as cross-reactivity
test, spike recovery test in future works.
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